14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
XMAX vs ADIL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ADIL Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 7–1 Matrix Metrics)
ADIL Overall Winner
6-Pillar Tally: XMAX 0 – 3 ADIL (3 Tie)
Matrix Metrics: XMAX 1 – 7 ADIL
As of Nov 20, 2026, Adial Pharmaceuticals, Inc (ADIL) is the stronger overall head-to-head candidate over XMAX (XMAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). XMAX carries a Unified Composite Score of 46.4/100 (HOLD) at $6.01 (N/M Forward P/E, N/A operating margin), whereas ADIL carries 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While XMAX currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. ADIL 32.8/100 SELL), ADIL captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: XMAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile ADIL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XMAX vs ADIL. Trailing 12-month operating profitability (XMAX N/A vs ADIL 0.0%) and valuation multiples (XMAX N/M vs ADIL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ADIL Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XMAX vs ADIL Key Questions & Quantitative Answers
As of Nov 20, 2026, Adial Pharmaceuticals, Inc (ADIL) is the stronger overall head-to-head candidate over XMAX (XMAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). XMAX carries a Unified Composite Score of 46.4/100 (HOLD) at $6.01 (N/M Forward P/E, N/A operating margin), whereas ADIL carries 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While XMAX currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. ADIL 32.8/100 SELL), ADIL captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: XMAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile ADIL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ADIL leads the Growth & Scale pillar: XMAX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ADIL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XMAX generates N/A in USD-normalized revenue versus N/A for ADIL. In operating R&D and SG&A reinvestment, XMAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADIL.
XMAX and ADIL trade at balanced relative valuation multiples. XMAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ADIL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XMAX (N/A ROE) versus ADIL (-2011.6% ROE) capital efficiency.
In options market volatility and institutional positioning, XMAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.90β · 195% Vol realized risk). By comparison, ADIL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 153% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.